Key points are not available for this paper at this time.
and NO to enhance SDT and reverse immunosuppression, leading to an increase in the immune response for cancer immunotherapy.
Ji et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: